Principal Investigator
Byron Lam
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20211219
Clinical Trial Summary
A PHASE 1/2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU400 FOR RETINITIS PIGMENTOSA ASSOCIATED WITH NR2E3 AND RHO MUTATIONS.
Phase
Phase I/II
Funding Agency/Sponsor
Intramural
Disease
Other